Catalog No.A2013 Synonyms: MEDI4736 Humanized and Non-humanized mouse model applicable
For research use only. Not for use in humans.
Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Choose Selective PD-1/PD-L1 Inhibitors
|Description||Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.|
Durvalumab (anti-PD-L1) is a potent antagonist of PD-L1 function, blocking interaction with PD-1 and CD80 to overcome inhibition of primary human T-cell activation. It does not trigger antibody-dependent cellular cytotoxicity (ADCC).
|In vivo||In vivo MEDI4736 significantly inhibits the growth of human tumors in a novel xenograft model containing coimplanted human T cells. In patients with advanced solid tumors, The linear clearance, volume of distribution and concentration at half maximal elimination (KM) of MEDI4736 are 240 mL/day, 3.6 L and 0.4 μg/mL, respectively. The half-life is ~23 days at doses ≥ 3 mg/kg Q2W. Greater than 99% target saturation (soluble and membrane bound) is expected at ≥40 μg/mL of MEDI4736.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles|
If you have any other enquiries, please leave a message.